Bajaj Healthcare Ltd
Incorporated in 1993, Bajaj Healthcare Ltd manufactures a wide range of Active Pharmaceutical Ingredients and Formulations[1]
- Market Cap ₹ 1,082 Cr.
- Current Price ₹ 322
- High / Low ₹ 516 / 272
- Stock P/E 19.2
- Book Value ₹ 158
- Dividend Yield 0.31 %
- ROCE 11.5 %
- ROE 9.40 %
- Face Value ₹ 5.00
Pros
Cons
- The company has delivered a poor sales growth of -1.44% over past five years.
- Company has a low return on equity of 3.96% over last 3 years.
- Dividend payout has been low at 12.2% of profits over last 3 years
- Promoter holding has decreased over last 3 years: -8.90%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 218 | 223 | 231 | 327 | 370 | 410 | 657 | 680 | 646 | 473 | 543 | 611 | 628 | |
| 189 | 193 | 200 | 288 | 327 | 362 | 521 | 561 | 534 | 397 | 460 | 506 | 519 | |
| Operating Profit | 29 | 30 | 31 | 39 | 43 | 48 | 136 | 119 | 112 | 76 | 83 | 105 | 109 |
| OPM % | 13% | 14% | 13% | 12% | 12% | 12% | 21% | 17% | 17% | 16% | 15% | 17% | 17% |
| 0 | 0 | 2 | 2 | 1 | 7 | 7 | 1 | -19 | -105 | 16 | -32 | -32 | |
| Interest | 8 | 8 | 8 | 8 | 8 | 7 | 8 | 13 | 18 | 30 | 28 | 22 | 23 |
| Depreciation | 9 | 9 | 11 | 11 | 11 | 12 | 16 | 18 | 17 | 28 | 28 | 28 | 29 |
| Profit before tax | 12 | 14 | 14 | 23 | 24 | 36 | 119 | 90 | 58 | -86 | 43 | 23 | 25 |
| Tax % | 37% | 39% | 43% | 33% | 33% | 30% | 30% | 20% | 25% | -3% | 7% | 33% | |
| 8 | 8 | 8 | 15 | 16 | 25 | 83 | 71 | 43 | -84 | 40 | 16 | 18 | |
| EPS in Rs | 8.34 | 3.04 | 2.83 | 5.50 | 5.91 | 9.14 | 30.11 | 25.87 | 15.59 | -30.36 | 12.51 | 4.68 | 5.76 |
| Dividend Payout % | 0% | 0% | 0% | 5% | 0% | 0% | 5% | 6% | 6% | -3% | 8% | 32% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | -1% |
| 3 Years: | -2% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | -11% |
| 3 Years: | 3% |
| TTM: | 20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | -6% |
| 3 Years: | 1% |
| 1 Year: | -27% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | 4% |
| Last Year: | 9% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 7 | 7 | 7 | 7 | 14 | 14 | 14 | 14 | 14 | 16 | 17 |
| Reserves | 78 | 82 | 92 | 107 | 122 | 164 | 245 | 315 | 354 | 265 | 450 | 516 |
| 70 | 81 | 75 | 87 | 81 | 91 | 181 | 257 | 415 | 333 | 223 | 249 | |
| 38 | 39 | 45 | 68 | 57 | 74 | 86 | 136 | 115 | 154 | 144 | 141 | |
| Total Liabilities | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 898 | 765 | 833 | 923 |
| 108 | 130 | 128 | 127 | 128 | 162 | 208 | 270 | 366 | 253 | 238 | 248 | |
| CWIP | 1 | 1 | 0 | 2 | 1 | 5 | 57 | 52 | 22 | 7 | 3 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| 79 | 78 | 91 | 140 | 137 | 170 | 260 | 399 | 510 | 506 | 591 | 667 | |
| Total Assets | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 898 | 765 | 833 | 923 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28 | 25 | 22 | 17 | 25 | 21 | 44 | 1 | -22 | 92 | 22 | 58 | |
| -17 | -31 | -8 | -12 | -13 | -28 | -109 | -75 | -93 | -11 | -15 | -48 | |
| -11 | 5 | -13 | 2 | -13 | 3 | 75 | 62 | 131 | -97 | -6 | 24 | |
| Net Cash Flow | -0 | -0 | 0 | 7 | -0 | -4 | 10 | -12 | 16 | -16 | 0 | 35 |
| Free Cash Flow | 11 | -6 | 14 | 5 | 11 | -2 | -70 | -74 | -115 | 73 | 10 | 18 |
| CFO/OP | 99% | 100% | 88% | 57% | 89% | 62% | 58% | 9% | -10% | 138% | 32% | 53% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 86 | 70 | 83 | 90 | 77 | 88 | 55 | 99 | 110 | 139 | 169 | 140 |
| Inventory Days | 50 | 56 | 45 | 57 | 45 | 54 | 94 | 143 | 199 | 206 | 206 | 249 |
| Days Payable | 63 | 46 | 51 | 74 | 45 | 80 | 67 | 94 | 81 | 128 | 122 | 133 |
| Cash Conversion Cycle | 73 | 80 | 78 | 73 | 77 | 62 | 82 | 148 | 228 | 217 | 254 | 256 |
| Working Capital Days | -11 | -17 | -4 | 0 | 12 | 24 | 34 | 40 | 27 | -0 | 140 | 119 |
| ROCE % | 16% | 13% | 13% | 16% | 16% | 18% | 36% | 20% | 14% | 8% | 11% | 11% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Manufacturing Facilities count |
|
||||||||||
| Total Workforce count |
|||||||||||
| API Installed Capacity MT per month |
|||||||||||
| Formulation Installed Capacity Million pieces per month |
|||||||||||
| Number of Countries Served count |
|||||||||||
| Alkaloid Processing Capacity - Opium Gum MT per annum |
|||||||||||
| Alkaloid Processing Capacity - Poppy Straw MT per annum |
|||||||||||
| Cumulative DMFs Filed count |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
- Intimation of allotment of equity shares pursuant to exercise of ESOPs
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
- DCGI approves Cenobamate API and tablets; Bajaj Healthcare first to launch in India across six strengths.
-
Announcement under Regulation 30 (LODR)-Credit Rating
- Ind-Ra upgrades Bajaj Healthcare’s bank loan ratings to IND A/Stable and IND A1 on August 6, 2026.
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Announcement under Regulation 30 (LODR)-Newspaper Publication
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1][2][3]
BHL is focused on development, supply, manufacturing of Amino Acids, Nutritional Supplements and Active Pharma Ingredients for Pharmaceutical, Nutraceuticals and Food industries. It manufactures active pharmaceutical ingredients and formulations in the form of tablets, capsules, powder, etc. for ~550+ clients, exporting bulk drugs to ~62+ countries in Europe, USA, Africa, Australia, etc.